Tango Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $4,117 | $11,607 | $19,875 | $6,471 |
Gross Profit | 4,117 | 11,607 | 19,243 | 5,846 |
EBITDA | -40,290 | -32,256 | -28,920 | -41,630 |
EBIT | -40,910 | -32,878 | -29,552 | -42,255 |
Net Income | -37,670 | -29,167 | -25,551 | -37,914 |
Net Change In Cash | 4,117 | 11,607 | 19,875 | 6,471 |
Free Cash Flow | -36,771 | -33,505 | -23,927 | -38,052 |
Cash | 69,530 | 53,148 | 51,566 | 61,163 |
Basic Shares | 109,226 | 108,507 | 108,314 | 108,171 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $42,069 | $36,527 | $24,860 | $37,042 |
Gross Profit | 42,069 | -78,671 | 24,860 | 37,042 |
EBITDA | -145,595 | -111,758 | -109,463 | -57,293 |
EBIT | -114,173 | -111,071 | -58,190 | |
Net Income | -130,302 | -101,744 | -108,176 | -58,235 |
Net Change In Cash | 42,069 | 36,527 | 24,860 | 37,042 |
Cost of Revenue | -81,066 | 114,364 | ||
Free Cash Flow | -131,501 | -119,508 | -116,772 | -61,364 |
Cash | 69,530 | 66,385 | 59,968 | 142,745 |
Basic Shares | 109,226 | 94,572 | 87,820 | 62,108 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.34 |
2024-09-30 | -$0.27 |
2024-06-30 | -$0.24 |
2024-03-31 | -$0.35 |
